Teva Pharma strong sales growth helped by acquisitions – The Pharma Letter (subscription)
Published February 16, 2012 | 
|
Teva Pharma strong sales growth helped by acquisitions
The Pharma Letter (subscription) The increase in branded revenues was primarily due to the inclusion of Cephalon sales (mainly Provigil (modafinil) with $ 350 million in revenues, Treanda (bendamustine) with $ 131 million and Nuvigil (armodafinil) with $ 86 million). |
